In vivo and in vitro activity of a bis-arylidenecyclo-alkanone against fluconazole-susceptible and -resistant isolates of Candida albicans

•Antifungal activity of 2,6-bis[(E)-(4-pyridyl)methylidene]cyclohexanone (PMC) was evaluated.•PMC presented MICs similar to those of fluconazole against Candida albicans.•PMC was non-toxic to murine macrophages and human erythrocytes in vitro.•Treatment with PMC was effective in invertebrate and mur...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of global antimicrobial resistance. 2018-09, Vol.14, p.287-293
Hauptverfasser: de Sá, Nívea Pereira, de Paula, Lídia Fátima José, Lopes, Larissa Ferreira Finamore, Cruz, Lana Ivone Barreto, Matos, Thelma Tirone Silvério, Lino, Cleudiomar Inácio, de Oliveira, Renata Barbosa, de Souza-Fagundes, Elaine Maria, Fuchs, Beth Burgwyn, Mylonakis, Eleftherios, Johann, Susana
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Antifungal activity of 2,6-bis[(E)-(4-pyridyl)methylidene]cyclohexanone (PMC) was evaluated.•PMC presented MICs similar to those of fluconazole against Candida albicans.•PMC was non-toxic to murine macrophages and human erythrocytes in vitro.•Treatment with PMC was effective in invertebrate and murine models of C. albicans infection. Candida albicans is a commensal organism and opportunistic pathogen associated both with superficial (mucosal and cutaneous) and systemic infections. Extensive use of antifungal agents has led to reduced susceptibility to the few existing drugs, which has encouraged the search for novel antifungal agents. Therefore, the present study investigated the antifungal activity of 2,6-bis[(E)-(4-pyridyl)methylidene]cyclohexanone (PMC) against C. albicans. The in vitro activity of PMC was evaluated against C. albicans. Additionally, an invertebrate infection model in Caenorhabditis elegans as well as two infected murine models of oral and systemic candidiasis were used to determine the antifungal efficacy of PMC in vivo. Minimum inhibitory concentrations (MICs) of PMC ranged from 4–32μg/mL against nine clinical and two reference C. albicans isolates. Interestingly, PMC inhibited filamentation in vitro at subinhibitory concentrations similar to fluconazole. PMC also showed low toxicity against murine macrophages and human erythrocytes. In the invertebrate infection model, PMC was efficient in prolonging survival of C. elegans infected with C. albicans SC5314. Treatment with PMC was efficient both in murine models of systemic and oral candidiasis and was similar to that observed with conventional drug treatments (nystatin and fluconazole). The results of this study indicate the therapeutic potential of PMC as it was able to inhibit filamentation of C. albicans in vitro. These alterations to the fungi by PMC resulted in a reduction of oral and systemic infection in mice. In conclusion, we present promising evidence of the anticandidal activity of PMC in vitro and in vivo.
ISSN:2213-7165
2213-7173
DOI:10.1016/j.jgar.2018.04.012